SCHEMBL2909379

SCHEMBL2909379

O=C1CC(Cl)C(=O)N1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5842293 0.72
SCHEMBL11715864 0.72
SCHEMBL6571045 0.70
SCHEMBL28416771 0.65 POLB (0.32)
SCHEMBL11753834 0.63 ALDH1A1 (0.40)
SCHEMBL15918875 0.63
SCHEMBL10568754 0.61 ALDH1A1 (0.54)
SCHEMBL9350619 0.61 ALDH1A1 (0.54)
SCHEMBL432048 0.58
SCHEMBL6058527 0.56 KMT2A (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851418-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-12-26 US disclosed
CN-112080011-B Dendritic macromolecule quaternary ammonium salt compound and preparation method and application thereof 惠州卫生职业技术学院 2022-08-16 CN disclosed
US-20210276976-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-09-09 US disclosed
EP-1879884-B1 AZOLE-BASED PHOSPHODIESTERASE INHIBITORS RANBAXY LAB LTD (IN) 2010-08-25 EP disclosed
EP-1879884-A1 AZOLE-BASED PHOSPHODIESTERASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117653-A1 AZOLE-BASED PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed
EP-1300406-B1 Method for producing pyridine compound EISAI CO LTD (JP) 2004-10-06 EP disclosed
US-6555559-B1 Prostaglandin I2 (PGI2); use as an anti-Helicobacter agent, a platelet function potentiating agent or a cervical ripening agent; side effect reduction TORAY INDUSTRIES, INC. (JP) 2003-04-29 US disclosed
EP-0724582-B1 PREPARATION OF OMEPRAZOLE AND LANSOPRAZOLE AND INTERMEDIATES USEFUL THEREIN TORCAN CHEMICAL LTD (CA) 2001-10-10 EP disclosed
EP-1044972-A1 5,6,7-TRINOR-4,8-INTER-m-PHENYLENE PGI2 DERIVATIVE AND DRUGS CONTAINING THE SAME TORAY INDUSTRIES, INC. (JP) 2000-10-18 EP disclosed
US-5502195-A Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole TORCAN CHEMICAL LTD. (CA) 1996-03-26 US disclosed
US-5470983-A Preparation of omeprazole and lansoprazole, and intermediates useful therein TORCAN CHEMICAL LTD. (CA) 1995-11-28 US disclosed
US-5374730-A Preparation of omeprazole and lansoprazole TORCAN CHEMICAL LTD. (CA) 1994-12-20 US disclosed
EP-0389162-B1 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives TORAY INDUSTRIES (JP) 1993-12-08 EP disclosed
US-5086071-A Improved chemical stability and ppotent in vivo TORAY INDUSTRIES, INC. (JP) 1992-02-04 US disclosed
EP-0389162-A1 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives TORAY INDUSTRIES, INC. (JP) 1990-09-26 EP disclosed